We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Commission based its approval on a Phase 3 clinical trial showing vision improvement as early as 30 days following treatment. Vision improved for 90 percent of trial subjects. Read More
The FDA announced the first biosimilar of Roche’s blockbuster cancer drug Rituxan (rituximab) — approving Teva and Celltrion’s Truxima (rituximab-abbs) for treating non-Hodgkin’s lymphoma. Read More